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ABSTRACT: 242 Background
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an autosomal dominant disorder predisposing humans to cutaneous and uterine leiomyomas; in 20% of affected families, type 2 papillary renal cell cancers (PRCCII) also occur with aggressive course and poor prognosis. HLRCC results from heterozygous germline mutations in the tumor suppressor fumarate hydratase (FH) gene.
Methods
As part of the French National Cancer Institute (INCa) "Inherited predispositions to kidney cancer" network, we performed sequence analysis and a functional study of FH in 56 families with clinically proven or suspected HLRCC and in 23 patients with isolated PRCCII (5 familial and 18 sporadic).
Results
We identified 32 different germline FH mutations (15 missense, six frameshifts, four nonsense, one deletion/insertion, five splice site and one complete deletion) in 40/56 (71.4%) families with proven or suspected HLRCC and in 4/23 (17.4%) probands with PRCCII alone, including 2 sporadic cases. Twenty-one of these were novel and all were demonstrated as deleterious by significant reduction of FH enzymatic activity. In addition, five asymptomatic parents in three families were confirmed as carrying disease-causing mutations.
Conclusions
This study identified and characterized 21 novel FH mutations and demonstrated that PRCCII can be the only one manifestation of HLRCC. Due to the incomplete penetrance of HLRCC, we propose to extend the FH mutation analysis to every patient with PRCCII 4 occurring before 40 yrs of age or when renal tumor harbors characteristic histologic features, in order to discover previously ignored HLRCC-affected families.
INTRODUCTION
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC, OMIM 605839) is an autosomal dominant familial disorder characterized by the development of cutaneous and uterine (fibroid) leiomyomas, renal cell carcinoma (RCC), and rarely uterine leiomyosarcomas. [1, 2] HLRCC was previously called multiple cutaneous and uterine leiomyomatosis (MCUL, OMIM 150800), as the association between skin and uterine leiomyomas was described before the discovery of RCC predisposition. Cutaneous leiomyomas occur in 76% of individuals at a mean age of 25 years (range: 10-47 years) but 40% percent of individuals have mild cutaneous manifestations with five or fewer lesions. [3, 4] Uterine leiomyomas are present in almost all women with a mean age at diagnosis of 30 yrs (range: 18-52 years). [3] [4] [5] RCC occurrence is relatively low (20%, 29/144 families worldwide) and differs between and within families affected by HLRCC. [1, 3, 4, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] RCCs predominantly affect young (< 40 years) adults with a mean age at diagnosis of 46 yrs (range: 17-75 years). [25] They are usually solitary, unilateral, and highly aggressive with rapid dissemination. The main histological RCC subtype is type 2 papillary RCC (PRCCII), a variety of renal cancer characterized by large tumor cells with eosinophilic cytoplasm and pseudostratified nuclei. [17, 25, 26] Less frequently, collecting duct RCC may also be observed in patients with HLRCC. [4, 25] MCUL/HLRCC is associated with heterozygous germline mutations in the fumarate hydratase (or fumarase, FH) gene located at 1q42.3-q43. [2, 3, 6] Interestingly, homozygous and compound heterozygous FH mutations have been first identified in fumarase deficiency, a rare autosomal recessive disorder characterized by neurological impairment and death in the first decade of life (FHD; MIM 136850, OMIM 606812). [27] [28] [29] FH spans 22 kb, contains 10 exons, and encodes two fumarase isozymes, mitochondrial and cytosolic. The active form of FH is a homotetramer in which three of the four chains combine to form the enzymatic active site. [7, 30, 31] FH catalyzes the conversion of fumarate to malate in the mitochondrial matrix as part of the tri-carboxylic acid (TCA) 6 cycle. Thus, FH deficiencies result in chronic accumulation of fumarate and altered levels of other TCA intermediates.
Fumarate accumulation has been shown to induce activation of hypoxia-inducible factor (HIF) and its target genes. [32] HIF plays a major role in the tissue response to hypoxia by inducing expression of multiple genes involved in cell survival and proliferation. In renal cancers and fibroids from HLRCC patients, alpha subunits of HIF (HIF1a and 2a) are overexpressed. [32, 33] Moreover, mice with inactive Fh1 in the kidney developed proliferative renal cysts overexpressing HIF alpha subunits and hypoxia pathway factors. [34] FH alteration induces fumarate accumulation and the production of reactive oxygen species, leading to activation of the HIF alpha subunits through inhibition of prolyl hydroxylase (PHD2), triggering the VHL-dependent degradation of HIF alpha subunits under normoxia. [35] Therefore, FH inactivation seems to be implicated in inappropriate activation of oncogenic hypoxia pathways, similar to the manner in which VHL germline mutations result in von Hippel-Lindau disease, the main cause of hereditary clear cell RCC (CCRCC). However, in contrast to the frequent observation of somatic VHL mutations in sporadic CCRCCs, to date no FH mutations have been detected in sporadic PRCCIIs. [36] To date, four complete deletions of FH, one exon deletion, one exon duplication, and 81 different FH germline point mutations have been reported in 144 MCUL/HLRCC families (Supplementary Table S1 ). [1, 3, 4, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [37, 38] There is no obvious relationship between genotype and the aggressiveness of the disease. All these mutations lead to the loss of FH enzymatic activity; the remaining functional allele is lost in most cutaneous, uterine, and renal tumors arising in patients carrying FH germline heterozygous mutations. [6, 7] The function of FH is then consistent with the function of tumor suppressor genes. [6] 7 As part of the French National Cancer Institute (INCa) "Inherited predispositions to kidney cancer" network, we performed the first comprehensive genetic and functional analysis of FH in a large series of patients with phenotypes highly suggestive of MCUL/HLRCC disease and in patients with only PRCCII. These analyses enhance our knowledge of the FH germline mutational spectrum and expand the group of phenotypic features associated with these FH mutations.
MATERIALS AND METHODS
Patient selection
Families were selected for inclusion in the study through two clinical approaches. 
Genomic rearrangement screening
DNA was extracted from peripheral blood leukocytes according to standard procedures using the QIAamp DNA Blood Midi Kit (Qiagen, Valencia, CA).Quantitative real-time PCR based on SYBR-Green fluorescence technology was used to detect genomic rearrangements (large deletions or duplications of one exon or more). PCR was performed with the QuantiFast SYBR Green PCR Kit (Qiagen) on an ABI 7700 Sequence Detection System (Applied Biosystems). Primers designed for sequencing analysis were used at a concentration of 300 nM. A total of 20 ng DNA was used in a 25 µL reaction volume. The BRCA1 gene was used as an internal reference. The copy number was determined using the 2-ΔCT method where ΔCT = CTFH amplicon -CTreference gene . [39] 9
Sequencing analysis
Mutations in FH gene were screened by genomic DNA amplification of each exon and splice junction (primer sequences and PCR conditions available upon request). PCR products from genomic rearrangement screening were first purified using the ExoSAP-IT PCR purification kit (USB) and then sequenced with the Big Dye Terminator v.3.1 kit (Applied Biosystems). Resin Sephadex G50 superfine (Amersham) was used for purification. Sequencing was performed on an ABI3730 automatic DNA sequencer (Applied Biosystems) in 96-well plates. Variants and mutations were identified by visual inspection of the sequence with Seqscape 2.5 software (Applied Biosystems).
Measurement of FH enzyme activity
Lymphoblastoid cell lines (LCL) were generated by Epstein-Barr virus transformation of leukocytes from 20 patients with novel missense or splice mutations and eight wild-type controls. Peripheral blood lymphocytes (PBL) were isolated on Ficoll cushion. LCL and PBL were homogenized in a lyses buffer (50 Mm Tris-HCl pH 7.2 containing 10% Triton X100, 2mM Phenylmethylsulfonyl fluoride and 0.02% of 2-mercaptoethanol) and subjected to brief sonication. Samples were centrifuged at 10.000 g for 20 mn at 4°C and the supernatants were used for the enzyme assay. FH enzymatic activity was measured spectrophotometrically according to standard procedures. [40, 41] Briefly the assay monitors the increase in absorbance at 250 nm due to fumarate production from malate, with a final reaction medium consisting of 50 mM malate, 50 mM phosphate buffer pH 7.8,
The FH activity was reported as the amount of fumarate generated per min per milligram of 10 protein, or in a ratio to the corresponding citrate synthase activity, final results are then expressed as percentage of control activity.
RESULTS
Mutation analysis
FH genotyping was carried out on germline DNA and sequencing of the entire gene Table 1 .
We completed the FH mutational spectrum by exploring large deletion or duplication events and identified one patient with a complete FH deletion (proband of family F1, Table   1 and Figure 1 ).
Twenty-one of the identified mutations have never been described previously (noted "this report" in Table 1 ), and none of these mutations was found in control DNA samples (0/360 alleles sequenced). These novel mutations included seven missense (p.Leu168Pro, p.His192Arg, p.Gln211Arg, p.Phe269Ser, p.Leu272Pro, p.Asn330Asp, p.Gln343Arg), two nonsense (p.Glu270X, p.Trp457X), six frameshifts (c.127_128delGA, c.47delT, c.298delA, c.666delC, c.810delA, c.994delA), one insertion-deletion (p.Leu374_His375insdelTyr) and five splice site (138+1_138+10del10, 247_249+1delGAGGinsA, 250-2A>G,426+1G>A, 11 1108-2A>G). Another mutation (p.Ala274Val) was identified by our group during the study but was published as a case report.
[42] Four novel mutations were found in unrelated French families (F9 and F10; F11, F12 and F13; F24 and F25; F32 and F33, respectively) from different areas and there was no evidence of common ancestors. Interestingly, 3 out of 4 mutations identified in probands with isolated PRCCII were also novel ( Table 1) .
We then performed an in silico analysis of the putative functional consequences of the missense mutations. As shown in Figure 2 , all FH missense mutations identified in the present study affect residues that have been highly conserved throughout evolution.
Functional characterization of novel mutations
In order to demonstrate the functional consequences of germline FH mutations, we measured the enzymatic activity of endogenous FH in peripheral blood lymphocytes or lymphoblastoid cells derived from patients. We tested 30 patients carrying an FH mutation (including 15 unpublished mutations, of which eight are novel missense mutations) and eight samples of the wild-type FH gene. Reduction of enzymatic activity by at least 50%
was observed for all mutations tested (Table 1) . We did not notice a major difference in the enzymatic activities of missense mutations (from 34.6% to 54.7% activity compared to a wild-type control, mean activity 45%) and total loss-of-function mutations such as deletions, nonsense mutations, or splice site mutations (from 39.5% to 60.8%, mean activity 50.1%). 
Family
Clinical findings
Clinical data could be recovered for 151 relatives belonging to the 44 families with a FH mutation and are summarized in Table 2 The clinical history of the patient with p.Ala274Val mutation was detailed in a very recent paper because of the unique association of cutaneous leiomyomatosis with cutis verticis gyrata, disseminated collagenoma and Charcot-Marie-Tooth's disease. [40] There was no clear genotype-phenotype correlation specially regarding the occurrence of renal tumors. On the other hand, we observed an intrafamilial phenotypic heterogeneity as illustrated in figure 3 . Moreover, genetic testing was positive in five asymptomatic (20- doubled the number of known splice site mutations (identified in 8 families (18.2%) in the present study versus seven (4.9%) previously described worldwide), emphasizing the importance of careful analysis of non-coding sequences surrounding splice sites. We found only one family with large deletion thus confirming that germline copy loss of FH is a rare genetic event (only four large deletions and one deletion of exon 1 in 144 HLRCC families described). [6] In order to evaluate the potential deleterious effect of novel nucleotide variations identified in the FH gene, we measured the enzymatic activity of endogenous fumarate hydratase in lymphoblastoid cells derived from patients. Reduction of, at least, 50% of the enzymatic activity was observed for all mutations tested thus supporting a model of loss of function and haploinsufficiency. Mutant FH proteins have been postulated to exert a dominant negative effect based on FH enzymatic activity [4, 6, 7] ; this hypothesis is supported by in vitro over-expression experiments in which the R190H FH mutant induced 60% inhibition of the endogenous enzymatic activity. [44] As the active FH enzyme is a 18 homotetramer, it is theoretically possible that missense mutations may affect FH activity more drastically than nonsense mutations; these mutations could disrupt the formation of nearly all wild-type homotetramers, leaving only one in 16 (1/24) tetramers composed of exclusively wild-type subunits. Therefore, a missense variant behaving as a strong dominant negative could dramatically reduce enzymatic activity of heterotetrameric FH.
Such molecular behavior has never been described, and we did not notice a major difference in the enzymatic activities of missense mutations versus total loss-of-function mutations. Therefore, we conclude that the missense allele products do not exert a strong dominant negative effect in vivo.
Genotype-phenotype relationships between the FH mutational spectrum and HLRCC manifestations have been previously proposed. For example, p.Arg58X FH mutations have been associated with a high frequency of kidney cancers [4] , but the carrier of this mutation in our series did not develop RCC by the age of 62 years. The p.Gly354Arg mutation has been reported to predispose patients exclusively to fibroids [7, 45] , but we found this mutation in families that displayed various phenotypes of skin lesions and renal cancers. In addition, several mutations that have been described in families with RCCs (p.Arg190Cys, p.Arg300X, p.Asn330Ser) or without RCCs (p.His137Arg) were associated with the opposite phenotype in our study. Phenotype heterogeneity is also observed within families ( Figure 3) . Therefore, there is to date no convincing evidence of a relationship between the type of FH mutation and the resulting disease phenotype.
We observed FH mutations in only 71.4% (40/56) of the MCUL/HLRCC families included in our study, a lower ratio compared with previous reports. This difference may be due to the recruitment of probands who not fulfill all clinical criteria of the HLRCC disease 19 (specially patients with isolated cutaneous leiomyomas or patients with uterine leiomyomas and RCC). On the other hand, these broad inclusion criteria allowed us to identify seven new families with HLRCC that would have not been detected otherwise. Indeed, the recruitment of patients by urologists allowed us to revise the percentage of families with RCC to 40% from the previously reported 20% (29/144 families). Concerning the percentage of all individuals with an FH mutation, we observed an RCC incidence of 17.9%, a figure similar to the 10-16% incidence previously described. [3] In addition, we describe FH germline mutations in two families with history of PRCCII only (no documented history of leiomyomatosis) and, for the fist time, in two patients with apparent sporadic PRCCII. The p.Ala74Pro mutation (family F41) has been previously reported in the context of HLRCC without RCC [6] ; however the splice site mutation c.426+1G>A (family F42), the p.Thr332fs mutation (family F44), and the p.Asn330Asp mutation (family F43) are novel. Interestingly, the unaffected father of family F44
proband's can be considered an obligate carrier, knowing that his mother and two of his brothers developed PRCCII. Consequently, we expanded the FH genotyping to relatives of the patients diagnosed with an FH mutation (58 more family members). As a result, we identified 5 patients with FH germline mutations who lacked any manifestation of the disease similarly to families described in [4] . (affected with an apparent sporadic PRCCII) was performed after FH mutation identification and revealed a small cutaneous leiomyoma.
In addition to the potential implications for presymptomatic diagnosis, identification of patients with FH germline mutations could also be critical for the determination of the appropriate treatment of advanced PRCCII. Indeed, as hereditary PRCCIIs are characterized by HIF overexpression and activation of angiogenesis [32] , it would be useful to explore the efficacy of anti-angiogenic drugs in patients affected by such tumors.
Recently, prolonged progression-free survival times were reported in 2/12 patients with apparent sporadic PRCCII treated by sunitinib, a novel tyrosine kinase inhibitor. [46] Further investigation is needed, but preliminary observation showed that one of these two patients presented cutaneous leiomyomas and is certainly a carrier of a germline FH mutation. Thus, it would be of great interest to explore the potential predictive role of FH mutations in therapy response. Gene copy number for all FH exons detected in control DNA and in patient's DNA. 
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